T. Rowe Price Associates’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

T. Rowe Price Associates’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-535,315	Closed	-$2.46M	–	2642
2020 Q2	$2.46M	Sell	535,315 -55,768	-9%	-$247K	﹤0.01%	1493
2020 Q1	$1.96M	Sell	591,083 -122,199	-17%	-$559K	﹤0.01%	1501
2019 Q4	$4.36M	Sell	713,282 -37,596	-5%	-$155K	﹤0.01%	1419
2019 Q3	$3.13M	Sell	750,878 -45,358	-6%	-$362K	﹤0.01%	1458
2019 Q2	$10.4M	Buy	796,236 +144,535	+22%	+$1.77M	﹤0.01%	1310
2019 Q1	$6.2M	Buy	651,701 +600	+0.1%	+$2.38K	﹤0.01%	1379
2018 Q4	$2.01M	Buy	+651,101	New	+$2.58M	﹤0.01%	1558

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

T. Rowe Price Associates's PHAS Position: Q3 2020 in Review

T. Rowe Price Associates sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2020, closing a stake of 535,315 shares — an estimated $2.46M sold.

T. Rowe Price Associates first reported a position in PHAS in Q4 2018 and held it in 7 quarters. The position peaked at $10.4M in Q2 2019. 50 funds tracked by Wall St. Rank hold PHAS as of Q3 2020.

T. Rowe Price Associates reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
T. Rowe Price Associates sold 535,315 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $2.46M.
T. Rowe Price Associates first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 7 quarters.
T. Rowe Price Associates's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $10.4M in Q2 2019.
50 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on T. Rowe Price Associates's 13F filing for Q3 2020, filed 16 Nov 2020.